Prosthetic Heart Valve Market Size, Share & Trends Analysis Report By Product (Transcatheter Heart Valve, Tissue Heart Valve, Mechanical Heart Valve), By Material (Metal Alloys, Pyrolytic Carbon, Biological Tissue, Polymers), By End-User (Hospitals, Ambulatory Surgical Centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Prosthetic Heart Valve Market Size & Growth Analysis

The global prosthetic heart valve market size was valued at USD 10.26 billion in 2025 and is projected to grow from USD 11.14 billion in 2026 to USD 21.58 billion by 2034, registering a CAGR of 8.61% during the forecast period from 2026 to 2034. North America dominated the prosthetic heart valve market with a market share of 49.52% in 2025.

The global market includes a range of products such as transcatheter heart valves, tissue heart valves, and mechanical heart valves, catering to patients with various valvular heart diseases, including aortic, mitral, tricuspid, and pulmonary disorders. These valves are manufactured from different materials, including metal alloys, pyrolytic carbon, biological tissue, and polymers, each selected based on durability, biocompatibility, and patient-specific requirements. The valves are implanted across multiple healthcare settings, primarily hospitals, ambulatory surgical centers, and other specialized cardiac care facilities, with the choice of setting depending on the complexity of the procedure and patient condition.

Product Insights

The transcatheter heart valve segment dominated the market in 2025 with a revenue share of 48.35%. The growth is attributed to the technological advancements in transcatheter valve design, shorter recovery times, and reduced procedural risks compared to traditional surgical valve replacement.

Mechanical Heart Valve segment is anticipated to register the fastest CAGR of 9.25%, owing to its exceptional durability, often lasting 20 years or more. This makes them particularly suitable for younger patients who require a long-term solution. In addition, they are also more cost-efficient over the long term due to their durability, reducing the need for repeated surgeries or valve replacements.

Request Customizationto receive a tailored report.

Material Insights

The biological tissue segment is anticipated to grow at a CAGR of 9.54% during 2026 - 2034. This growth is attributed to the increasing preference for biocompatible and durable valve materials, as well as rising adoption of minimally invasive procedures using biological tissue valves.

Pyrolytic carbon dominated the market in 2025, with a revenue share of 32.21%, owing to its excellent biocompatibility, which minimizes adverse immune responses and reduces the risk of complications such as hemolysis. This property ensures that the valve functions safely, making it suitable for lifelong implantation in patients.

End-User Insights

The hospitals segment dominated the market in 2025, with a revenue share of 65.02%. The growth is attributed to the availability of advanced surgical facilities, higher patient inflow for cardiac procedures, and the preference for hospitals as primary centers for complex prosthetic heart valve implantation and postoperative care. Additionally, hospitals offer access to multidisciplinary care teams, and innovative diagnostic and monitoring equipment, ensuring better patient outcomes. The presence of specialized cardiac units, comprehensive pre and post-operative services, and the ability to handle high risk or complicated cases further reinforce hospitals as the preferred choice for prosthetic heart valve procedures.

The ambulatory surgical centers (ASCs) is anticipated to register the fastest CAGR during the forecast period, owing to the increasing adoption of minimally invasive transcatheter valve replacement procedures and the growing preference for outpatient procedures, which require shorter recovery times and lower costs.

Speak to an Analystto discuss market opportunities.

Regional Analysis

The North America region dominated the market with a revenue share of 49.52% in 2025. The growth is attributed to factors such as well well-established healthcare infrastructure for cardiac care, including advanced hospitals, specialized heart centers, and skilled cardiologists. This robust infrastructure facilitated the adoption of innovative prosthetic heart valve technologies and ensures timely, high quality treatment for patients with valvular heart diseases.

The global market in U.S. is widely driven by the FDA’s expanded approval of transcatheter aortic valve replacement (TAVR) for low-risk patients. This decision opens access to a much larger population, directly boosting the market size.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Market Insights

The Asia Pacific region is the fastest-growing region with a CAGR of 9.90% during the forecast timeframe, driven by local manufacturing initiatives for prosthetic heart valves, which have enhanced accessibility and affordability by reducing dependence on imports. Industrial incentives and specialized medical device parks are further promoting innovation and high-quality local production.

India continues to position itself in the global market, due to the government’s expansion of the Ayushman Bharat scheme, which covered advanced cardiac procedures including valve replacements. By improving patient access and reducing cost barriers, this policy directly boosted the market size. This unique support strengthens prosthetic heart valve market growth nationwide.

Europe Market Insights

Europe has a rapidly aging population with a high prevalence of aortic stenosis and other valvular heart diseases. Traditional open heart surgeries carry higher risks for elderly and high risk patients. As a result, the shift toward less invasive transcatheter solutions is accelerating market growth, particularly for next-generation valves that reduce recovery time, lower procedural complications, and improve quality of life.

The Prosthetic Heart Valve Market in the UK is propelling due to the National Health Service (NHS) funding expansion for minimally invasive valve replacement procedures. This public investment increased patient access and reduced waiting times, directly supporting market size. Such government-backed accessibility continued to accelerate global market growth across the UK.

Middle East and Africa Market Insights

The driving factor for the prosthetic heart valve market in the Middle East and Africa is the rising medical tourism for cardiac surgeries. Countries like the UAE, Saudi Arabia, and South Africa are emerging as regional hubs for advanced cardiac care, attracting patients from neighboring countries seeking high quality heart valve surgeries. This trend is boosting demand for advanced prosthetic heart valves and minimally invasive procedures, as hospitals invest in modern technologies and skilled cardiac specialists to cater to international patients.

The growing integration of digital imaging and 3D printing for pre-surgical planning drives the market growth. Cardiac surgeons in South Africa are increasingly using 3D printed patient specific heart valve models based on high resolution imaging (CT and MRI scans) to plan complex valve replacement procedures. This technology supported in reducing surgical risks, shortened operation times, and improved post operative outcomes. The Chris Hani Baragwanath Academic Hospital in Johannesburg implemented 3D printing for cardiac surgery planning, including prosthetic valve placements, enabling surgeons to tailor procedures to individual patients’ anatomy and thereby boosting demand for customized prosthetic valves.

Latin America Market Insights

The increasing focus on hybrid cardiac procedures combining surgical and interventional approaches, further drives the market growth. Leading cardiac centers are adopting hybrid operating rooms that allow surgeons to perform complex valve replacements using a combination of minimally invasive techniques and traditional surgery in a single procedure. This approach improves outcomes for high risk patients and drives demand for advanced prosthetic valves compatible with both surgical and transcatheter implantation.

Increasing adoption of remote patient monitoring and tele cardiology for post operative care, drives the market growth. Hospitals and clinics are implementing digital platforms to monitor patients after valve replacement surgeries, allowing timely detection of complications and reducing hospital readmissions. This trend encouraged surgeons to adopt advanced prosthetic valves with longer durability and compatibility with remote monitoring devices, improving patient outcomes and confidence in surgical interventions. Hospital Italiano de Buenos Aires integrated tele cardiology programs for post operative valve patients, supporting the use of next-generation prosthetic heart valves while enhancing follow up care.

Competitive Landscape

The global market is moderately fragmented with a few major players dominating, such as Edwards Lifesciences Corporation, Medtronic, Boston Scientific Corporation, and Others, while several regional and emerging companies contribute to competition.

Abbott: An emerging market player

Abbott is an emerging player in the prosthetic heart valve market, focused on advancing minimally invasive transcatheter valve technologies with enhanced precision, expanded indications, and global accessibility.

• In May 2025, Abbott’s Tendyne transcatheter mitral valve system gained FDA approval for high-risk patients with severe mitral annular calcification (MAC).

List of Key and Emerging Players in Prosthetic Heart Valve Market